Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RT 100

Drug Profile

RT 100

Alternative Names: Ad5-AC6; Ad5.hAC6; Adenylate cyclase gene therapy - Renova; RT100

Latest Information Update: 05 Oct 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Renova Therapeutics
  • Class Gene therapies
  • Mechanism of Action Adenylate cyclase expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure

Most Recent Events

  • 05 Oct 2020 Phase II development for Heart failure is still ongoing in USA (Renova Therapeutics pipeline, September 2020)
  • 05 Jun 2019 Renova Therapeutics withdraws the phase III FLOURISH trial for Heart failure in USA due to the clinical development plans and strategy for RT 100 being re-evaluated (Intracoronary) (NCT03360448)
  • 19 Dec 2017 RT 100 receives Fast Track designation for Heart failure [Intracoronary] in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top